This $1,104,029 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in non-ambulatory individuals with Duchenne muscular dystrophy (DMD). The research will be conducted over a 3-year period from November 1, 2024 to October 31, 2027. The funding will enable the University of...
The University of Florida was awarded a $1,166,594 project grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "EARLY CARDIAC BIOMARKERS OF INFLAMMATION AND REMODELING IN DMD," will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The project will investigate innovative approaches to address critical health challenges related...
This $1,525,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports foundational studies at the University of Florida to understand the phenotypic, region-specific, and cell-specific dysregulation in the central nervous system of individuals with myotonic dystrophy. The 4-year award, effective May 15, 2024, will enable the university to conduct innovative research to advance the understanding of this neurological...
The University of Florida (UF) received a $1,524,836 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding and targeting common mechanisms of myotonic dystrophy types 1 and 2 using novel repeat expansion mouse models. The grant, which began on September 1, 2023 and will continue through August 31, 2027, supports UF's cutting-edge biomedical research efforts to transform healthcare for Service...
The University of Florida was awarded a $5.796 million Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of September 1, 2023 through August 31, 2027. The grant will support the development of clinical candidates for the treatment of Myotonic Dystrophy at the University's location in Gainesville, Florida. As the prime awardee, the University will leverage its expertise in biomedical research to...
Under a $1,525,000 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development), the University of Florida's Division of Sponsored Research will conduct research to "UNDERSTANDING AND TARGETING COMMON MECHANISMS OF MYOTONIC DYSTROPHY TYPES 1AND 2 USING NOVEL REPEAT EXPANSION MOUSE MODELS." This 4-year research project, commencing on Sep 1, 2023, will advance the understanding and treatment of myotonic dystrophy, a genetic disorder that...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
The University of Florida was awarded a $305,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from March 2021 through March 2024 to develop novel therapies for dystonia. Through this funding, the University of Florida Division of Sponsored Research will conduct research into medical solutions for dystonia that can potentially transform healthcare for service members and the...
The University of Florida was awarded a $152,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2025, supports advanced biomedical research aimed at "Targeting TIE2 as a Novel Strategy in VEGFR Inhibitor-Resistant Angiosarcoma" with a performance period ending on July 31, 2027. The Military Medical Research and Development program funds a diverse portfolio of scientific...